What happened
From June 5 to 8, the American Diabetes Association held its 86th Scientific Sessions in New Orleans, the single largest gathering of diabetes and obesity doctors in the world. More than 12,000 clinicians and researchers attended, and a wave of new drug data was presented for the first time.
The theme this year was a real shift in how the field talks about these medicines. For years the only number that mattered was weight lost. This year the conversation moved to what else the drugs do, to muscle, to the heart, to the years a person is healthy, and to who keeps the weight off after they stop.
The names worth knowing
A few new drugs dominated the meeting. You do not need to memorise them, but you will hear them, so here is the plain version:
- Retatrutide (Eli Lilly): the triple-action drug behind the field's biggest weight-loss number to date. Still in trials, not yet available.
- CagriSema (Novo Nordisk): a two-in-one injection that pairs semaglutide with a second hormone. Strong results, but the reception was measured.
- Survodutide and oral elecoglipron: two more contenders, including a pill, showing this field is about to get much more crowded.
What it means for you
None of these are something you can ask for at your next appointment yet. The drug your prescriber can actually offer today is still semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), and how you use it is what decides your results this year.
But the direction of travel is the useful part. The whole field is now focused on the same thing Steady was built around: the scale is the least interesting number. What you keep, your muscle, your energy, your steadiness, is the real measure of how a year on these drugs actually goes.
We read the conference so you do not have to. The deeper pieces are in our research hub.
